S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
Log in
NASDAQ:CALA

Calithera Biosciences Stock Forecast, Price & News

$3.56
-0.08 (-2.20 %)
(As of 09/23/2020 02:50 PM ET)
Add
Compare
Today's Range
$3.54
Now: $3.56
$3.71
50-Day Range
$3.55
MA: $4.03
$5.08
52-Week Range
$2.45
Now: $3.56
$8.18
Volume9,031 shs
Average Volume684,545 shs
Market Capitalization$251.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Read More
Calithera Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.25 million
Book Value$2.24 per share

Profitability

Net Income$-89,860,000.00

Miscellaneous

Employees90
Market Cap$251.19 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$3.56
-0.08 (-2.20 %)
(As of 09/23/2020 02:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

How has Calithera Biosciences' stock price been impacted by COVID-19?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CALA shares have decreased by 31.9% and is now trading at $3.56.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Calithera Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Calithera Biosciences
.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Calithera Biosciences
.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) posted its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.29) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.04.
View Calithera Biosciences' earnings history
.

What price target have analysts set for CALA?

5 Wall Street analysts have issued 12-month price objectives for Calithera Biosciences' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Calithera Biosciences' stock price to reach $8.13 in the next twelve months. This suggests a possible upside of 128.2% from the stock's current price.
View analysts' price targets for Calithera Biosciences
.

Who are some of Calithera Biosciences' key competitors?

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Plug Power (PLUG), Camtek (CAMT) and Rigel Pharmaceuticals (RIGL).

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 66, Pay $887.04k)
  • Mr. Curtis C. Hecht, Chief Bus. Officer (Age 49, Pay $538.17k)
  • Dr. Keith Orford, Chief Medical Officer (Age 48, Pay $793.85k)
  • Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 46)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (10.56%), BVF Inc. IL (10.05%), Point72 Asset Management L.P. (5.81%), Great Point Partners LLC (3.21%), Marshall Wace North America L.P. (1.94%) and Sofinnova Investments Inc. (1.47%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong, Susan Molineaux and Value Fund L P Biotechnology.
View institutional ownership trends for Calithera Biosciences
.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Nuveen Asset Management LLC, Point72 Asset Management L.P., State of Wisconsin Investment Board, UBS Group AG, and Grimes & Company Inc.. Company insiders that have sold Calithera Biosciences company stock in the last year include Bvf Partners L P/Il, and Stephanie Wong.
View insider buying and selling activity for Calithera Biosciences
.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Marshall Wace North America L.P., Federated Hermes Inc., Assenagon Asset Management S.A., Sofinnova Investments Inc., Man Group plc, Two Sigma Advisers LP, and Swiss National Bank. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux, and Value Fund L P Biotechnology.
View insider buying and selling activity for Calithera Biosciences
.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $3.56.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $251.19 million and generates $22.25 million in revenue each year. The biotechnology company earns $-89,860,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Calithera Biosciences employs 90 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is www.calithera.com.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.